摘要
目的:分析真实世界慢性肾衰竭患者应用参芎葡萄糖注射液的联合用药特征。方法:从中国中医科学院中医临床基础医学研究所建立的医院信息系统数据仓库中,提取应用过参芎葡萄糖注射液的683例慢性肾衰竭住院患者信息进行分析。结果:参芎葡萄糖注射液与西药呋塞米(305例,44.66%)、抗生素类药(507例,74.23%)联合应用最多,与中药金水宝胶囊(213例,31.19%)、补益剂(391例,57.25%)及活血化瘀剂(390例,57.10%)联合应用最多。结论:参芎葡萄糖注射液治疗慢性肾衰竭的联合用药基本符合慢性肾衰竭中西医结合治疗指南及其本虚标实的基本病机,可减少慢性肾衰竭患者尿蛋白,保护肾功能,或可缓解慢性肾衰竭患者心血管病变以及改善认知功能。
Objective： Analyse Shenxiong glucose injection combined with other medications for patients with chronic renal failure in real world. Methods： Analysed the informations of 683 hospitalized patients with chronic renal failure,the date collected from the hospital information system of Institute of Basic Research in Clinical Medicine of China Academy of Chinese Medical Sciences. Results： In combined application, the western medicine with highest use frequency was furosemide（ 305 cases,44. 66%） and antibiotics（ 507 cases,74. 23%）; the traditional Chinese medicine with highest use frequency was Jinshuibao capsules（ 213 cases,31. 19%）,tonifying formula（ 391 cases,57. 25%）,blood-activating and stasis-resolving medicinal（ 390 cases,57. 1%）. Conclusion： Shenxiong glucose injection combined with other medications in the treatment of chronic renal failure basically conformed to the guideline for the treatment of chronic renal failure in integrative medicine practice and conformed to basic pathogenesis of deficiency in origin and excess in superficiality.Shenxiong glucose injection could decrease proteinuria and improve renal function in patients with chronic renal failure,may be also alleviate cardiovascular disease and improve cognitive function.
出处
《中国中医基础医学杂志》
CAS
CSCD
北大核心
2018年第2期218-221,248,共5页
JOURNAL OF BASIC CHINESE MEDICINE
基金
国家科技重大专项项目(2015ZX09501004-001-009)-中药上市后安全性风险信号临床评估及机理研究
中医药行业科研专项课题(201507003-8)-中医特色健康管理的缺血性中风病复发风险评估-早期预警系统研发及示范应用
北京市中医药科技发展专项(JJ2014-53)-中西药联合应用评价及机制的方法研究
中国中医科学院自主选题研究项目课题(第九批)(Z0406)-循证中医药证据核心科学问题深化研究
